ArticleCureus2025
Therapeutic Plasma Exchange in a Rare Case of Metastatic Pancreatic Carcinoma Presenting as Thrombotic Microangiopathy and Acute Kidney Injury.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombotic microangiopathy (TMA) represents a diverse group of conditions characterized by the presence of microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and ischemic end-organ injury. Thrombotic thrombocytopenic purpura (TTP) is an important cause of TMA requiring urgent identification and therapeutic plasma exchange (TPE). Cancer-related TMA is commonly misdiagnosed as TTP. In contrast to TTP, there is no clear evidence supporting the routine use of TPE in TMA associated with cancers. However, there are some case reports showing that TPE may also be useful in TMA not associated with TTP, such as cancer-related TMA. In fact, there are different postulated pathophysiology leading to this disease entity. Here, we present a rare case of TMA and acute kidney injury (AKI) secondary to metastatic pancreatic carcinoma who had a resolution of bleeding symptoms with complete hematological and renal recovery after four sessions of daily TPE. The patient finally died of cancer six months later. Our case shows that TPE could be valuable in cancer-related TMA in particular patients, especially those with clinical bleeding and thrombosis. The ability of TPE to remove abnormal components in the complement pathway and potential endothelial-damaging agents or autoantibodies and replace them with normal ones may explain its usefulness in some patients with cancer-related TMA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.